CCS
ATRC icon

Crosspoint Capital Strategies’s AtriCure ATRC Stock Holding History

Crosspoint Capital Strategies’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-800
Closed -$15K – 516
2014
Q1 		$15K Buy
+800
New +$16.4K 0.01% 405

Other funds holding ATRC

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crosspoint Capital Strategies's ATRC Position: Q2 2014 in Review

Crosspoint Capital Strategies sold out of AtriCure (ATRC) in Q2 2014, closing a stake of 800 shares — an estimated $15K sold.

Crosspoint Capital Strategies first reported a position in ATRC in Q1 2014 and held it in 1 quarter. The position peaked at $15K in Q1 2014. 113 funds tracked by Wall St. Rank hold ATRC as of Q2 2014.

  • Crosspoint Capital Strategies reported no remaining AtriCure position as of Q2 2014 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 800 AtriCure shares in Q2 2014, an estimated $15K.
  • Crosspoint Capital Strategies first reported a position in AtriCure in Q1 2014 and held it in 1 quarter.
  • Crosspoint Capital Strategies's AtriCure position peaked at $15K in Q1 2014.
  • 113 funds tracked by Wall St. Rank held AtriCure as of Q2 2014.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2014, filed 29 Jul 2014.